RXRX vs COAG
Side-by-side comparison of price performance, valuation, growth, profitability, analyst targets and technical trend.
RXRX · Recursion Pharmaceuticals$3.52 ▲ 0.57%
COAG · Hemab Therapeutics Holdings$49.02 ▲ 7.57%
One year, rebased to 100
Each line starts at 100 so growth is directly comparable
- RXRX +3.8%
- COAG +44.2%
Head to head
| Metric | RXRX | COAG |
|---|---|---|
| Price | $3.52 | $49.02 |
| Change today | ▲ 0.57% | ▲ 7.57% |
| Market cap | $2.19B | $2.29B |
| Return, 3 months | +7.0% | -1.7% |
| Return, year to date | -13.9% | – |
| Return, 1 year | -23.8% | – |
| P/E (TTM) | – | – |
| P/B | 2.4 | 5.0 |
| P/E percentile vs own 5y | 60th | 37th |
| Dividend yield | – | – |
| Revenue growth (YoY, latest qtr) | -61.8% | – |
| Net profit growth (YoY) | +23.8% | -97.8% |
| Gross margin | 1.8% | – |
| Operating margin | -1,008.5% | – |
| Net margin | -962.0% | – |
| Return on equity | -56.6% | -18.3% |
| Analyst target vs. price | +88.4% | +27.5% |
| Analyst buy share | 40% | 100% |
| RSI (14) | 44 | 78 |
| 30-day volatility | 111.1% | 70.5% |
| Max drawdown, 1 year | -54.9% | -48.4% |
| Trend read | Leaning bearish | Strong uptrend |
| Analyst consensus | Buy | Buy |
Green cells mark the best value in each row where "better" is clear-cut (lower P/E, higher margin). That is a reading of the numbers, not a recommendation. Financials are in each company's reporting currency.
What the numbers say
- COAG is the largest of the group by market value.
- COAG has been the calmest stock over the last 30 days.